According to GlobalData’s company profile on Indivior, Nanoparticle drug conjugates was a key innovation area identified from patents. Indivior's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230225961A1) describes a method for preventing opioid overdose or symptoms caused by accidental exposure to an opioid agonist. The method involves self-administering a parenteral injection of a pharmaceutical formulation using an auto-injection device. The formulation contains an effective amount of nalmefene and/or its salt or solvent.

The effective amount of nalmefene in the formulation ranges from about 0.5 mg to about 3.0 mg. Additionally, the formulation may include an isotonicity agent (0.1 mg to 6.0 mg), a stabilizing agent (optional), and an acid or base to achieve a pH of 3.4-4.4. The parenteral injection can be administered intramuscularly or subcutaneously.

The pharmaceutical formulation may also contain about 2.7 mg to 4.5 mg of an isotonicity agent and an aqueous solution of about 100 µL to 1.0 mL. The method is applicable to individuals who may experience incidental exposure to opioid agonists, such as healthcare professionals, emergency medical service personnel, law enforcement officers, military members, security personnel, or untrained individuals. It is particularly relevant for those involved in the investigation or clean-up of opioid agonist production, transport, or distribution sites.

The pharmaceutical formulation is substantially free of antimicrobial preservatives and remains stable for approximately twelve months at 25°C. It can be administered prior to incidental exposure to an opioid agonist, ranging from 5 minutes to 6 hours before exposure. The formulation aims to prevent symptoms of opioid overdose, including respiratory depression, central nervous system depression, cardiovascular depression, altered level of consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing, erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting.

The method ensures that the subject's plasma concentration of nalmefene reaches its maximum (Tmax) in less than 30 minutes, with occupancy at opioid receptors of greater than 90% or 95%. The formulation provides at least 4 to 6 hours of protection against opioid-induced respiratory depression following administration.

Overall, this patent describes a method for preventing opioid overdose or symptoms resulting from accidental exposure to opioid agonists. The method involves self-administering a parenteral injection of a pharmaceutical formulation containing nalmefene or its equivalent, which can be administered prior to exposure and provides several hours of protection against respiratory depression.

To know more about GlobalData’s detailed insights on Indivior, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies